Japan M&A, Prescription for Growth

Although cross-border acquisitions by Japanese drugmakers come with hefty price tags, they may be just what the industry needs to counter uncertain sales and enrich pharma pipelines

Japanese pharmaceutical companies—some of the most sophisticated and cash-rich in the world—are shopping abroad for targets to enrich their drug pipelines and counter the uncertain outlook for sales in Japan. But sellers are still insisting on hefty price-tags, despite slowing economic growth and depressed equity markets.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.